Moderna
2Q Revenues: $241 million (-30%)
2Q Loss: $1.3 billion (loss of $1.4B 2Q23)
Comments: Decline in revenues is attributable to decreased sales of the Company’s COVID-19 vaccine. The company reported $184 million in Spikevax (COVID-19 vaccine) sales in the quarter, down 37%, which includes $162 million of U.S. sales and $22 million of international sales.
 
Cost of sales in the quarter was $115 million, which included third-party royalties of $10 million, unutilized manufacturing capacity and wind-down costs of $55 million, and inventory write-downs of $14 million. R&D expenses increased 6% in the quarter to $1.2 billion.
 
The company received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July, and received EMA positive opinion in June. The vaccine is recommended for all unvaccinated people 75 and older and unvaccinated people ages 60-74 who are at increased risk for RSV.